Altmış Beş Yaş ve Üstü Hastaların Robotik Stereotaktik Radyoterapi Sonuçları ve Tedaviye Uyumu

Abstract

Objective: This study aims to report the robotic fractionated stereotactic radiotherapy (FSRT) results and treatment compliance in patients ≥65 years of age. Material and Methods: Retrospective reviews of 39 patients aged 65 years and older treated with CyberKnife® FSRT were performed. Karnofsky Performance Status (KPS) of 72% of the patients were ≥70, and 33% of the patients had comorbid illnesses. Patients were classified according to diagnosis: brain metastasis (n=22), primary brain tumor (n=6), vertebral metastasis (n=4), locally recurrent nasopharyngeal cancer (n=3), orbital tumor (n=3), and early-stage lung cancer (n=1). Median age was 69 years (range, 65-81 years). FSRT was performed as a re-irradiation in 62% of all patients. Results: Median follow-up for all groups of patients was 6 months (range, 1-36 months). In all groups, one patient presented with grade 2 hearing impairment during the 16-month follow-up (Common Terminology Criteria for Adverse Events, v 3.0). For one patient in the brain metastasis group, the treatment was delayed for 3 days because of neutropenia. There were no acute grade 3-4 toxicities. In the brain metastasis group, median overall survival was 5 months (CI: 1.2-8.7); 5-month and 7-month overall survival rates were 50% and 33%, respectively. One-year progression-free survival rate of the 14/22 evaluable patients with brain metastases was 63.5%. Conclusion: Robotic FSRT is a non-invasive and well tolerated treatment modality for this age group of patients.